A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
Condition(s) studied
Investigational drug(s) / intervention(s)
PF-08165784: Taken by mouth (PO)
Fulvestrant: Selective Estrogen Receptor Degrader (SERD)
Atirmociclib: Selective CDK4 inhibitor
Cetuximab: Monoclonal antibody (EGFR inhibitor)
Letrozole: Nonsteroidal aromatase inhibitor
Study summary
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-08165784) when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment given to stop the growth of cancer. This study also aims to find the best amount of study medication that can be given to patients.
This study is seeking participants with a specific type of breast cancer called hormone receptor-positive (HR+), HER2- negative (HER2-) breast cancer, or colorectal cancer (cancer of the colon or rectum), that has a change (mutation) in a gene called PIK3CA. The cancer must be advanced or metastatic, meaning it has spread to other parts of the body or cannot be completely removed with surgery.
All participants in this study will take the study medication (PF-08165784) as a tablet by mouth. The participant may take the medicine at the study clinic during study visits or at home. Treatment will be given in 28-day cycles and will continue for as long as the participant remains in the study. Depending on which part of the study participants are enrolled into, they will receive the study medication (PF-08165784) alone or in combination with other anti-cancer medications.
Eligibility
Primary outcome measure(s)
- Part 1 (Dose Escalation): Number of participants with Dose-Limiting Toxicities (DLT) — Baseline up to 28 days
Any adverse events that are attributable to one, the other, or both study treatments, occurring in the DLT observation period are considered DLTs, excluding toxicities clearly due to underlying disease or extraneous causes. - Part 1 (Dose Escalation): Incidence of Adverse Events (AEs) — From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it. - Part 1 (Dose Escalation): Number of participants with laboratory abnormalities — From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
Number of participants with laboratory test abnormalities. - Part 2 (Dose Expansion): Objective Response Rate (ORR) — Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
ORR defined as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
Trial sites (5)
| Facility | City | Region | Status |
|---|---|---|---|
| Highlands Oncology Group, PA | Fayetteville | Arkansas | |
| Highlands Oncology Group, PA | Rogers | Arkansas | |
| Highlands Oncology Group, PA | Springdale | Arkansas | |
| START Midwest, LLC | Grand Rapids | Michigan | |
| Pan American Center for Oncology Trials, LLC- Hospital Oncológico Office | San Juan | Puerto Rico |
More Pfizer trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07897721 on ClinicalTrials.gov ↗ ← All trials in the USA